retinitis pigmentosa
Conditions
Interventions
0.12% topical unoprostone isopropyl twice daily
0.25% topical nipradilol twice daily
Sponsors
Kyushu university hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) patients with retinitis pigmentosa (2) BCVA >= 0.1 (3) patinets whose agreement was shown by him/herself
Exclusion criteria
Exclusion criteria: (1) a past history of glaucoma or ocular hypertension (2) patients with another macular disorder, such as epiretinal membrane (3) a past history of using the test drug within 6 months (4) pregnant subjects, subjects suspected of being pregnant, or breast-feeding subjects (5) hypersensitivity to the test drug (6) a past history of the entry into another clinical trial within 1 year (7) inappropriate case judged by investigator or subinvestigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The efficacy of the treatment was monitored by the following parameters before and after treatment (6 months or 12 months). (1) best corrected visual acuity (2) visual field measurement testing using the Humphrey Field Analyzer (HFA: the central 10-2 Program) (3) retinal sensitivity measurement using microperimeter (MP-1) (4) retinal circulation measurement using Laser Speckle flowgrafy | — |
Countries
Japan
Outcome results
None listed